MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Study of KL340399 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: KL340399 injection
First Posted Date
2022-05-24
Last Posted Date
2024-06-27
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
30
Registration Number
NCT05387928
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath